Latest updates
View our press releases and follow Diasome’s path to Phase III Clinical Trials.
Press Release
February 18, 2020
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
Learn More
Press Release
February 18, 2020
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
Learn More
Press Release
February 18, 2020
Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
Learn More
Press Release
February 12, 2020
Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference
Learn More
Press Release
February 12, 2020
Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference
Learn More
Press Release
February 12, 2020
Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference
Learn More
Press Release
December 10, 2019
Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board
Learn More
Press Release
December 10, 2019
Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board
Learn More
Press Release
December 10, 2019
Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board
Learn More
Journal Article
September 30, 2019
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes
Learn More
Journal Article
September 30, 2019
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes
Learn More
Journal Article
September 30, 2019
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A Six-Month Phase 2b Study in Type 1 Diabetes
Learn More
Journal Article
September 26, 2019
A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.
Learn More
Journal Article
September 26, 2019
A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.
Learn More
Journal Article
September 26, 2019
A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.
Learn More
Press Release
September 24, 2019
Diasome Announces Publication of Phase 2b Results in Diabetes Care. First ever six-month study of a mealtime liver-targeted insulin.
Learn More
Press Release
September 24, 2019
Diasome Announces Publication of Phase 2b Results in Diabetes Care. First ever six-month study of a mealtime liver-targeted insulin.
Learn More
Press Release
September 24, 2019
Diasome Announces Publication of Phase 2b Results in Diabetes Care. First ever six-month study of a mealtime liver-targeted insulin.
Learn More
Press Release
June 25, 2019
Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
Learn More
Press Release
June 25, 2019
Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
Learn More
Press Release
June 25, 2019
Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes
Learn More
Interview
June 17, 2019
Bruce Bode, MD: Hypoglycemic Effect of Hepatic-Directed Insulin
Learn More
Interview
June 17, 2019
Bruce Bode, MD: Hypoglycemic Effect of Hepatic-Directed Insulin
Learn More
Interview
June 17, 2019
Bruce Bode, MD: Hypoglycemic Effect of Hepatic-Directed Insulin
Learn More
Press Release
June 10, 2019
Diasome’s Hepatocyte Directed Vesicle (HDV) Technology Met Primary Endpoint in Phase 2b Trial in Type 1 Diabetes
Learn More
Press Release
June 10, 2019
Diasome’s Hepatocyte Directed Vesicle (HDV) Technology Met Primary Endpoint in Phase 2b Trial in Type 1 Diabetes
Learn More
Press Release
June 10, 2019
Diasome’s Hepatocyte Directed Vesicle (HDV) Technology Met Primary Endpoint in Phase 2b Trial in Type 1 Diabetes
Learn More
Press Release
May 29, 2019
Diasome Announces Presentations at the American Diabetes Association’s 79th Scientific Sessions
Learn More
Press Release
May 29, 2019
Diasome Announces Presentations at the American Diabetes Association’s 79th Scientific Sessions
Learn More
Press Release
May 29, 2019
Diasome Announces Presentations at the American Diabetes Association’s 79th Scientific Sessions
Learn More
News Article
April 29, 2019
Diasome's Father-Son Developing Nanotech to Improve Insulin Effectiveness
Learn More
News Article
April 29, 2019
Diasome's Father-Son Developing Nanotech to Improve Insulin Effectiveness
Learn More
News Article
April 29, 2019
Diasome's Father-Son Developing Nanotech to Improve Insulin Effectiveness
Learn More
Media Relations
Cherilyn Cecchini, M.D.
LifeSci Communications
+1.646.876.7110
ccecchini@lifescicomms.com
